The contract research and development (R&D) safe harbour for generic pharmaceuticals is a significant compliance simplification mechanism under the Direct Tax Code (DTC) 2025. The safe harbour rules provide certainty on transfer pricing for generic pharmaceutical R&D services, with a prescribed operating profit margin of 24%. This guide explains the 24% margin threshold and the compliance requirements.
The Safe Harbour Framework for Generic Pharma R&D
Section 167 — Statutory Basis
Section 167(1) provides that the determination of income referred to in section 9(2) or arm's length price under section 165 or 166 shall be subject to safe harbour rules. Section 167(2) empowers the Board to make rules for safe harbour.
Section 167(3) — Definition of Safe Harbour
Section 167(3) defines "safe harbour" as circumstances in which the income-tax authorities shall accept the transfer price or income declared by the assessee. The word "shall" makes acceptance mandatory — income-tax authorities have no discretion to recompute the ALP or income once the conditions are met.
Contract R&D Safe Harbour for Generic Pharmaceuticals
Rule 88 — Eligible International Transactions
Rule 88 specifies that provision of contract research and development services, wholly or partly, relating to generic pharmaceutical drugs is an eligible international transaction for safe harbour.
Rule 89(2) — Safe Harbour Margin
The safe harbour margin for provision of contract research and development services relating to generic pharmaceutical drugs is:
Operating profit margin ≥ 24% (where aggregate operating revenue does not exceed ₹300 crore)
Revenue Cap
The safe harbour applies where the aggregate operating revenue of such transaction does not exceed a sum of ₹300 crore.
Definition of Generic Pharmaceutical Drug
Rule 86(g) defines "generic pharmaceutical drug" as a drug that is comparable to a drug already approved by the regulatory authority in dosage form, strength, route of administration, quality and performance characteristics and intended use.
Definition of Contract Research and Development Services
Contract R&D services relating to generic pharmaceutical drugs involve research and development activities conducted by an Indian entity on behalf of a foreign principal, with the foreign principal performing most of the economically significant functions and bearing the risks.
Eligibility Conditions
1. Eligible Assessee
Rule 87(1)(d) provides that the eligible assessee includes a person engaged in providing contract research and development services, wholly or partly, relating to generic pharmaceutical drugs, with insignificant risk, to a foreign principal.
2. Insignificant Risk
Rule 87(3) provides that for identifying an eligible assessee with insignificant risk, the Director General of Income-tax (Systems) shall have regard to the following factors:
- The foreign principal performs most of the economically significant functions involved in research or product development cycle
- The foreign principal or its other associated enterprises provides the funds or capital and other economically significant assets
- The eligible assessee works under the direct supervision of the foreign principal
- The eligible assessee does not assume or has no economically significant realised risks
- The eligible assessee has no ownership right, legal or economic, on the outcome of the research
3. Revenue Cap
The safe harbour applies where the aggregate operating revenue of such transaction does not exceed ₹300 crore.
Calculating Operating Profit Margin
Operating Revenue
Rule 86(o) defines "operating revenue" as the revenue earned by the assessee in the tax year in relation to the international transaction during the course of its normal operations, but does not include interest income, income from foreign currency fluctuations, income on transfer of assets, refunds relating to income-tax, provisions written back, extraordinary incomes, and other incomes not relating to normal operations.
Operating Expense
Rule 86(n) defines "operating expense" as the costs incurred in the tax year by the assessee in relation to the international transaction during the course of its normal operations, but does not include interest expense, provision for unascertained liabilities, pre-operating expenses, loss on foreign currency fluctuations, extraordinary expenses, loss on transfer of assets, expense on account of income-tax, and other expenses not relating to normal operations.
Operating Profit Margin
Operating profit margin is the ratio of operating profit (operating revenue in excess of operating expense) to operating expense, expressed in terms of percentage.
Illustration
If a generic pharma contract R&D provider has:
- Operating revenue from international transactions: ₹250 crore
- Operating expenses: ₹200 crore
- Operating profit: ₹50 crore
- Operating profit margin: 50/200 = 25%
Since 25% > 24%, the provider meets the safe harbour margin.
Procedure for Safe Harbour
Rule 90 — General Procedure
- Form No. 49: The assessee shall furnish Form No. 49 to the Assessing Officer on or before the due date for furnishing the return of income
- Return of Income: The return of income for the relevant tax year is to be furnished on or before the date of furnishing of Form No. 49
- Verification: The Assessing Officer shall verify whether the assessee is an eligible assessee and the transaction is an eligible international transaction
- Reference to Transfer Pricing Officer: If the Assessing Officer doubts the validity of the option, he shall make a reference to the Transfer Pricing Officer
- Order: The Transfer Pricing Officer shall, by order in writing, declare the option to be invalid or valid
- Objection: If the assessee objects to the order, he may file his objections with the Commissioner
Rule 91 — Procedure for IT Services
For IT services (including contract R&D in software development), the option for safe harbour, once exercised validly, shall continue to remain in force for a period of five consecutive tax years.
Exclusions
Rule 92 — Non-Application
Nothing contained in the safe harbour rules shall apply in respect of eligible international transactions entered into with an associated enterprise located in any country or territory notified under Section 176, or in a no tax or low tax country or territory.
Rule 93 — Mutual Agreement Procedure Not to Apply
Where transfer price in relation to an eligible international transaction is accepted under Section 167, the assessee shall not be entitled to invoke mutual agreement procedure under an agreement for avoidance of double taxation.
Practical Compliance
1. Assess Eligibility
- Determine whether the company is engaged in contract R&D for generic pharmaceuticals
- Determine whether the services are provided with insignificant risk
- Determine whether the aggregate operating revenue does not exceed ₹300 crore
2. Exercise Option
- File Form No. 49 on or before the due date for furnishing the return of income
- Ensure the return of income is furnished on or before the date of filing Form No. 49
3. Maintain Documentation
- Even with safe harbour, documentation under Section 171 must be maintained
- Ensure the documentation is complete and accurate
4. Monitor Compliance
- Monitor operating profit margin to ensure it meets the 24% threshold
- Adjust pricing if necessary
- Maintain proper records
Consequences of Non-Compliance
Invalid Option
If the option is declared invalid, the transfer price will be determined under the regular transfer pricing provisions.
Penalties
Non-compliance may also result in:
- Penalty under Section 442 for failure to maintain documentation
- Penalty under Section 457 for failure to furnish information
Expert Legal Guidance
Anuj Desai & Associates provides comprehensive legal advisory services on contract R&D safe harbour for generic pharmaceuticals. Our direct tax experts help pharma companies understand the safe harbour conditions, exercise options, and navigate the regulatory framework. We assist in eligibility assessment, Form 49 filing, and representation before income-tax authorities.
Disclaimer: This article provides general information and does not constitute legal advice. For specific guidance on safe harbour rules or any other direct tax matter, please consult qualified legal professionals.
Need Expert Legal Guidance?
Navigating the complex contract R&D safe harbour framework for generic pharmaceuticals requires experienced legal counsel. At Anuj Desai & Associates, we provide comprehensive direct tax advisory services, including:
- Eligibility Assessment: Evaluation of safe harbour eligibility
- Option Exercise: Assistance with Form No. 49 filing
- Documentation: Assistance with transfer pricing documentation
- Representation: Representation before income-tax authorities
Contact us for expert legal guidance on your contract R&D safe harbour matters.